Compare Schlumberger NV (SLB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Zimmer Biomet Holdings Inc — how do they compare? Schlumberger NV trades at $48.97 (market cap $72.69B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Schlumberger NV is far larger — about 4.3× Zimmer Biomet Holdings Inc's market cap, and Schlumberger NV pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SLB | ZBH | |
|---|---|---|
Market Cap | $72.69B | $16.95B |
Volume | 16,228,451 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $60.10 | $103.98 |
52-Week Low | $31.72 | $79.58 |
Typical Hold Time | 99 Days | 89 Days |
Enterprise Value | $81.42B | $24.02B |
Dividend Yield | 2.41% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $47.96, down 4.08% on the day, amid a bearish technical signal. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Recent contract wins in the Rovuma Basin, Saudi Arabia, and Oman bolster revenue visibility. Cash flow from operations remains strong at $6.49B for 2025, though net cash flow was negative due to financing activities.
Analyst consensus is bullish with an 84.85% buy rating and a $64.58 price target, implying significant upside. Risks include exposure to oil price volatility and recent profit margin compression. The stock's current valuation metrics, including a P/E of 23.89, appear reasonable given growth prospects.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
